The import of pharmaceutical products to Malaysia has experienced varying trends over the last decade. From 2013 to 2017, there was a general decline in imports, with notable drops in 2015 and 2016. However, from 2018 onwards, the market witnessed a recovery with fluctuations. By 2023, imports stood at USD 1.6263 billion, marking a modest year-on-year increase of 2.34%. The 5-year CAGR leading up to 2023 showed an average annual increase of 1.88%. Future trends indicate a consistent growth pattern, with forecasts predicting the import value to reach USD 1.8091 billion by 2028, reflecting a 5-year CAGR of 1.56%. This signifies an 8.02% overall increase over the next five years.

Key future trends to watch for include:

Advancements in pharmaceutical technologies and biotechnology.
Malaysia’s healthcare policy changes and investment in healthcare infrastructure.
Potential impacts of global pharmaceutical supply chain adjustments post-pandemic.
Increased domestic pharmaceutical manufacturing capacity potentially affecting import needs.